Background: This study presents real-world evidence on effectiveness of sema OW in a large cohort of T2D patients.
Methods: Claims and lab result data were used to identify T2D patients who initiated sema OW between 2/1/18 - 4/30/19 (index as first claim). Patients selected had ≥1 A1c result within ≤3 months pre- and ≥3 months post-index. All patients and a group of patients persistent on sema OW (those with a sema OW prescription with days supply dispensed overlapping/in proximity of date of post-index A1c measurement) were assessed for A1c changes and were split into 4 subgroups: GLP-1 naïve, GLP-1 experienced and either group with pre-index A1c >9%.
Results: Of 1,888 patients initiating sema OW, 57.8% were GLP-1 naïve. A1c was significantly reduced in all patients (-0.9%) and subgroups (p<0.001, Figure 1). Persistent patients achieved a 1.1% A1c reduction, with similar or greater reductions across subgroups when compared to all patients. Attainment of A1c <7% increased from 23% pre- to 49% post-index for all patients (20 to 30% pre to post increase in each subgroup, all p<0.001).
Conclusion: Initiation of sema OW was associated with significant reduction in A1c and an increase in reaching A1c <7% regardless of a prior history of GLP-1 use. Sema OW also provides significant change in A1c among patients whose A1c was not controlled on their previous GLP-1.
J. Visaria: None. C. Uzoigwe: Employee; Self; Novo Nordisk Inc. C. Swift: Employee; Self; Novo Nordisk Inc. Stock/Shareholder; Self; Novo Nordisk Inc. Y.M. Paprocki: Employee; Self; Novo Nordisk Inc. Stock/Shareholder; Self; Novo Nordisk A/S. V. Willey: Employee; Self; HealthCore.